Locally advanced breast cancer in Saudi Arabia: High frequency of stage III in a young population

Medical Oncology

Volumn 16, Issue 2, 1999, Pages 95-103

  Ezzat, Adnan A ^a   Ibrahim, Ezzeldin M ^a   Raja, Madras A ^a   Al Sobhi, Saif ^a   Rostom, Assem ^a   Stuart, Robert K ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Breast cancer; Locally advanced disease; Saudi Arabia

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SAUDI ARABIA; TREATMENT OUTCOME;

EID: 0032776863     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02785842     Document Type: Article

References (38)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996, Ca-A Cancer J Clin 1996; 46: 5-27.
2. Parkin DM et al (eds). Cancer Incidence in Five Continent, vol. 6. IARC Scientific Publication no. 120. IARC: Lyon, 1992.
3. Mahboubi E. Epidemiology of cancer in Saudi Arabia, 1975-1985, Ann Saudi Med 1987; 7: 265-276.
4. Ezzat A et al. An overview of breast cancer. Ann Saudi Med 1997; 17: 10-15.
5. Al-Tamimi T et al. Cancer in the Eastern Region of Saudi Arabia: a population-based study (1987-1988). Ann Saudi Med 1997; 17(1): 53-66.
6. Omer YT, Gjorgov AN, Ismail AS, Tabik MA. Cancer trends in Kuwait (1974-1982). In: Khogali M, Omer YT, Gjorgov A, Ismail AS (eds). Cancer Prevention in Developing Countries. Pergamon: London, 1986, pp 25-34.
7. Henderson IC. Principles in the management of metastatic disease. In: Harris AL Jr, Henderson IC, Hellman S et al (eds). Breast Diseases. Lippincott: Philadelphia, PA, 1991, 547-665.
8. Ibrahim EM et al. Women's knowledge about and attitude toward breast cancer in a developing country: implications for program interventions. Results based on interviewing 500 women in Saudi Arabia. J Cancer Edu 1991; 6(2): 73-81.
9. Chlebowski RT, Lillington LM. A decade of breast cancer clinical investigation: results as reported in the program/ proceedings of the American Society of Clinical Oncology. J Clin Oncol 1994; 12: 1789-1795.
10. Harmanek P, Sobin LH. TNM Classification of Malignant Tumours. UICC International Union Against Cancer. Springer-Verlag: Berlin, 1987.
11. American Joint Committee on Cancer. Manual for Staging of Cancer, 4th edn. Lippincott: Philadelphia, 1992, 149-154.
12. Haagensen CD, Stout AP. Carcinoma of the breast: Criteria of inoperability. Ann Surg 1943; 118: 859-870.
13. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment, no. 48. WHO: Switzerland, 1979, pp 16-21.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958; 53: 457-481.
15. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
17. Cox DR, Oakes D. Regression models and life tables (with discussion). J Roy Statist Soc 1972; B34: 187-220.
18. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
19. Kay R. Proportional hazard regression models and the analysis of censored survival data. Appl Statist 1977; 26: 227-237.
20. Dixon WJ, Brown MB, Engleman L, Jennrich RI. BMDP Statistical Software Manual. University of California Press: Berkeley, 1990.
21. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. 1990; 54: 345-349.
22. Weil M et al. Long-term results of neoadjuvant chemotherapy (NAC) in breast cancer: is tumor response a useful prognostic factor? Fourth International Congress on Anti-cancer Chemotherapy. 2-5 February 1993, Paris, p 60.
23. Borrego M, Rebelo I. Locally advanced carcinoma of the breast initially treated with radiotherapy. Acta Med Port 1995; 8(6): 341-345.
24. Saarto T, Blomqvist C, Grohen P, Rissanen P, Elomaa I. The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with an without tamoxifen. Eight year follow-up results of a randomized trial. Eur J Surg Oncol 1995; 21: 146-150.
25. Fletcher G, Montague E. Carcinoma of the breast; criteria of operability. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 573-584.
26. Sheldon T et al. Primary radiation for locally advanced breast cancer. Cancer 1987; 60: 1219-1225.
27. Vora N et al. Local regional radiation therapy in patients with high-risk primary breast cancer receiving high-dose chemotherapy followed by stem cell rescue. Proceedings of the Annual Meeting of the American Society for Clinical Oncology 1994, 13: A220.
28. Pierce L, Adler D, Helvie M, Lichter A, Merajver S. The use of mammography in breast preservation in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1996; 34(3): 571-577.
29. Hoekman K et al. Primary high-dose chemotherapy with hematopoietic growth factors followed by surgery and radiotherapy in Stage III breast carcinoma: a phase II study in 15 patients. Ned Tijdschr Geneeskd 1994; 138(21): 1069-1073.
30. Brufman G et al. Neoadjuvant chemotherapy (cyclophosphamide, adriamycin, and 5FU) for clinical Stage III breast cancer., Proceedings of the Fourth International Congress on Anti-cancer Chemotherapy, 2-5 February, 1993, Paris, p 58.
31. Alvarez A et al. Multimodality treatment in Stage III breast cancer: our experience. Proceedings of the Annual Meeting of the American Society for Clinical Oncology 1993; 12: A131.
32. Torrecillas L et al. Analysis of clinical vs pathological response in locally advanced breast cancer after FAC (5-FU, adriamycin, cyclophosphamide) or FEC (5-FU, epirubicin, cyclophosphamide) neoadjuvant chemotherapy. Proceedings of the Annual Meeting of the American Society for Clinical Oncology 1993; 12: A142.
33. Ragaz J et al. Impact of the residual disease in Stage III breast cancer patients treated with preoperative (neoadjuvant) chemotherapy, radiotherapy, and mastectomy. Proceedings of the Annual Meeting of the American Society for Clinical Oncology 1994; 13: A88.
34. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994; 74 (Suppt): 416-423.
35. Rivkin SE et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol 1989; 7: 1229-1238.
36. Grohn P, Heinonen E, Klefstrom P, Tarkkanen J. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1984; 54: 670-674.
37. Masood S. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers. Surg Oncol Clin N Am 1995; 4(4): 601-632.
38. Gardin G et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 1995; 31A(9): 1428-1433.